2nd ESMO Consensus Conference on Lung Cancer: Non-small-cell lung cancer first-line/second and further lines in advanced disease

Benjamin Besse, A. Adjei, P. Baas, P. Meldgaard, M. Nicolson, L. Paz-Ares, M. Reck, E. F. Smit, Konstantinos Syrigos, R. Stahel, E. Felip, S. Peters, Keith Kerr, Johan Vansteenkiste, Wilfried Eberhardt, Martin Edelman, Tony Mok, Ken O'Byrne, Silvia Novello, Lukas BubendorfAntonio Marchetti, Paul Baas, Martin Reck, Peter Meldgaard, Alex Adjei, Marianne Nicolson, Lucio Crinò, Paul Van Schil, Suresh Senan, Corinne Faivre-Finn, Gaetano Rocco, Giulia Veronesi, Jean Yves Douillard, Eric Lim, Christophe Dooms, Walter Weder, Dirk De Ruysscher, Cecile Le Pechoux, Paul De Leyn, Virginie Westeel

Research output: Contribution to journalArticlepeer-review

210 Scopus citations

Abstract

To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines in advanced disease, early stage disease and locally-advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on 1st line / 2nd and further lines of treatment in advanced disease.

Original languageEnglish
Pages (from-to)1475-1484
Number of pages10
JournalAnnals of Oncology
Volume25
Issue number8
DOIs
StatePublished - Aug 1 2014

Keywords

  • Age Factors
  • Aged
  • Angiogenesis Inhibitors/therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols/therapeutic use
  • Carboplatin/administration & dosage
  • Carcinoma, Non-Small-Cell Lung/drug therapy
  • Chemotherapy, Adjuvant/methods
  • Cisplatin/administration & dosage
  • Combined Modality Therapy/methods
  • Consensus
  • Drug Substitution/methods
  • Humans
  • Lung Neoplasms/drug therapy
  • Maintenance Chemotherapy/standards
  • Neoadjuvant Therapy/methods

Fingerprint

Dive into the research topics of '2nd ESMO Consensus Conference on Lung Cancer: Non-small-cell lung cancer first-line/second and further lines in advanced disease'. Together they form a unique fingerprint.

Cite this